LGC’s Protein LC-MS/MS and Immunogenicity centres of excellence

LGC’s Protein LC-MS/MS and Immunogenicity centres of excellence


During the early stage of drug
development, pharmaceutical companies require highly-sophisticated analysis of
the drugs to demonstrate the pharmacodynamics, the safety and efficacy of the drug, and the pharmacokinetics, how the body metabolizes and eliminates the drug. With complex biological therapies, such as protein and antibody-based drugs,
it is also necessary to investigate possible immune reaction that the
patient might have. LGC has extensive expertise in the determination of small
molecules and bio-pharmaceuticals in biological matrices, using a range of
analytical platforms. This expertise helps our customers solve complex
challenges and develop cost-effective methods to screen potential future
medicines and therapies. “We’re a leading centre of excellence for bioanalysis,
with extensive capabilities for mass spectrometry and immunoassay, all in a
regulated environment.” We work closely with our customers to develop and
validate bio-analytical methods to analyze samples from early discovery
through to clinical trials. “In 2007, our labs pioneered the use of mass spectrometry to measure proteins in biological fluids, a technique that is
now widely recognized as a complementary alternative to immunoassay.” Through our
cutting-edge analytical science, our bioanalytical team plays a critical role in
helping to launch new treatments for illnesses such as cancer, heart disease,
diabetes and asthma, ultimately helping to improve the quality of people’s lives. LGC. Science for a safer world.

Add a Comment

Your email address will not be published. Required fields are marked *